Vol 7, No 2 (2021)
Review paper
Published online: 2021-07-21

open access

Page views 6619
Article views/downloads 1020
Get Citation

Connect on Social Media

Connect on Social Media

Historia diagnostyki i leczenia tocznia rumieniowatego układowego

Wiktor Schmidt12, Katarzyna Pawlak-Buś12, Piotr Leszczyński12
Forum Reumatol 2021;7(2):71-77.

Abstract

Toczeń rumieniowaty układowy (SLE, systemic lupus erythematosus) ze względu na liczne manifestacje kliniczne i laboratoryjne jest jedną z najbardziej złożonych jednostek chorobowych, z którymi mają do czynienia reumatolodzy w swojej praktyce klinicznej. Równie skomplikowana co sama choroba jest jej historia, której początki sięgają średniowiecza, ale właściwy opis choroby i identyfikacja poszczególnych manifestacji miała miejsce dopiero w drugiej połowie XX wieku. Historia SLE jest rozdziałem nadal otwartym — w ostatnich latach opracowano nowe kryteria klasyfikacyjne choroby, a także nowe,
skuteczne metody leczenia. Celem pracy było przybliżenie rysu historycznego tocznia rumieniowatego układowego z uwzględnieniem postępów w zakresie jego definicji, diagnostyki i leczenia.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Felten R, Lipsker D, Sibilia J, et al. The history of lupus throughout the ages. J Am Acad Dermatol. 2020 [Epub ahead of print].
  2. Smith CD, Cyr M. The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am. 1988; 14(1): 1–14.
  3. Bateman TA. Practical Synopsis of Cutaneous Diseases According to the Arrangement of Dr. Willan: Exhibiting a Concise View of the Diagnostic Symptoms and the Method of Treatment. Crissy. 1824.
  4. Cazenave P-LA, Schedel HÉ. Manual of Diseases of the Skin. Langley. 1846.
  5. von He, Canstatt B, Eisenmann G. Jahresbericht über die fortschritte der gesammten medicin in allen ländern. F Enke. 1845.
  6. Kohn M. Zum Wesen und zur Therapie des Lupus erythematosus. Archiv für Dermatologie und Syphilis. 1869; 1(1): 18–41.
  7. Neue Beiträge zurKenntniss des Lupus erythematosus. Archiv für Dermatologie und Syphilis. 1872; 4(1): 36–78.
  8. Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med Sci. 1895; 110: 629–646.
  9. Hutchinson J, Hutchinson J, Hutchinson J. Harveian Lectures on Lupus. Br Med J. 1888; 1(1410): 6–10.
  10. Sequeira JH, Balean H. Lupus Erythematosus: A Clinical Study of Seventy-One Cases. Br J Dermatol. 1902; 14(10): 367–379.
  11. Keith N, Rowntree LA. study of renal complications of disseminated lupus erythematosus: report of four cases. Trans Assoc Am Physicians. 1922; 37: 487–502.
  12. Baehr G, Klemperer P, Schifrin AA. diffuse disease of the peripheral circulation (usually associated with lupus erythematosus and endocarditis). Trans Assoc Am Physicians. 1935; 50: 139–155.
  13. Harvey AM, Shulman LE, Tumulty PA. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore). 1954; 33(4): 291–437.
  14. Haserick JR, Long R. Systemic lupus erythematosus preceded by false-positive serologic tests for syphilis: presentation of five cases. Ann Intern Med. 1952; 37(3): 559–565.
  15. Churg J, Sobin LH. Renal Disease: Classification and Atlas of Glomerular Diseases. Igaku-Shoin. 1982.
  16. Macleod J, Aberd MD, Lond M. A lecture on systemic lupus erythematosus: its nature and treatment. . The Lancet. 1908; 172(4444): 1271–1275.
  17. Pulay E. Stoffwechselpathologie und hautkrankheiten. Dermatol Wochenschr. 1921; 73: 1217–1234.
  18. Libman E, Sacks B. hitherto undescribed form of valvular and mural endocarditis. Archives of Internal Medicine. 1924; 33(6): 701–737.
  19. Burnham TK, Neblett TR, Fine G. The application of the fluorescent antibody technic to the investigation of lupus erythematosus and various dermatoses. J Invest Dermatol. 1963; 41: 451–456.
  20. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979; 115(12): 1409–1415.
  21. Bowen JT. Twentieth Century Practice of Medicine. N Y William Wood Co. 1896; 5: 691–708.
  22. Pillat A. Über das Vorkommen von Chorioiditis bei Lupus erythematodes. Albrecht von Græfes Archiv für Ophthalmologie. 1935; 133(4): 566–577.
  23. Daly D. Central nervous system in acute disseminate lupus erythematosus. J Nerv Ment Dis. 1945; 102: 461–465.
  24. Piper PG. Disseminated lupus erythematosus with involvement of the spinal cord. J Am Med Assoc. 1953; 153(3): 215–217.
  25. Russell PW, Haserick JR, Zucker EM. Epilepsy in systemic lupus erythematosus; effect of cortisone and ACTH. AMA Arch Intern Med. 1951; 88(1): 78–92.
  26. Afeltra A, Garzia P, Mitterhofer AP, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42(4): 599–608, doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.
  27. Reinhart A. Erfahrungen mit der Wassermann-Neisser-Bruckschen syphilis reaktion. Munch Med Wochenschr. 1909; 41: 1092–1097.
  28. Goeckerman WH. Lupus erythematosus as a systemic disease. JAMA: The Journal of the American Medical Association. 1923; 80(8): 542.
  29. Keefer E, Felty A. Acute disseminated lupus erythematosus. Bull Johns Hopkins Hosp. 1924; 35: 294–304.
  30. Lyon JM. Acute lupus erythematosus. Archives of Pediatrics & Adolescent Medicine. 1933; 45(3): 572.
  31. Rose E, Pillsbury DM. Acute disseminated lupus erythematosus — a systemic disease. Annals of Internal Medicine. 1939; 12(7): 951.
  32. Coburn A, Moore D. The plasma proteins in disseminate lupus erythematosus. Bull Johns Hopkins Hosp. 1943; 73: 196–221.
  33. Townes AS, Stewart CR, Osler AG. Immunologic studies of systemic lupus erythematosus. II. Variations of nucleoprotein-reactive gamma globulin and hemolytic serum complement levels with disease activity. Bull Johns Hopkins Hosp. 1963; 112: 202–219.
  34. Vaughan JH, Bayles TB, Favour CB. The response of serum gamma globulin level and complement titer to adrenocorticotropic hormone therapy in lupus erythematosus disseminatus. J Lab Clin Med. 1951; 37(5): 698–702.
  35. Hargraves M. Discovery of the LE cell and its morphology. Mayo Clin Proc. 1969; 9: 579–599.
  36. Miescher P, Fauconnet M. Absorption of L. E. factor by isolated cell nuclei. Experientia. 1954; 10: 252–253.
  37. Beck JS. Variations in the morphological patterns of "autoimmune" nuclear fluorescence. Lancet. 1961; 1(7188): 1203–1205.
  38. Tan EM, Schur PH, Carr RI, et al. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1966; 45(11): 1732–1740.
  39. Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol Baltim Md 1950. 1966; 96: 464–471.
  40. Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020; 16(10): 565–579.
  41. Pangborn MC. A New Serologically Active Phospholipid from Beef Heart. Experimental Biology and Medicine. 1941; 48(2): 484–486.
  42. Conley CL, Hartman RCA. hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952; 31: 621–622.
  43. Lee SL, Sanders MA. disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest. 1955; 34: 1814–1822.
  44. Bowie EJ, Thompson JH, Pascuzzi CA, et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963; 62: 416–430.
  45. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983; 2(8361): 1211–1214.
  46. Galli M, Barbui T, Comfurius P, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. The Lancet. 1990; 335(8705): 1544–1547.
  47. Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336(8708): 177–178.
  48. McNeil HP, Simpson RJ, Chesterman CN, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87(11): 4120–4124.
  49. Jayakody Arachchillage D, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol. 2014; 165(5): 609–617.
  50. Cohen A, Reynolds W, Franklin E, et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis. 1971; 21: 643.
  51. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11): 1271–1277.
  52. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725.
  53. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8): 2677–2686.
  54. Aringer M, Costenbader K, Dörner T, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(9): 1151–1159.
  55. Payne JA. postgraduate lecture on lupus erythematosus. Clin J. 1894; 4: 223–239.
  56. Bettley FR, Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951; 2(6687): 755–758.
  57. Lewis HM, Frumess GM. Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report. AMA Arch Derm. 1956; 73(6): 576–581.
  58. Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann Rheum Dis. 1949; 8(2): 97–104.
  59. Pollak VE, Pirani CL, Schwartz FD, et al. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med. 1964; 63(6): 537–550.
  60. Dubois EL. Nitrogen mustard in treatment of systemic lupus erythematosus. AMA Arch Intern Med. 1954; 93(5): 667–672.
  61. Austin H, Klippel J, Balow J, et al. Therapy of Lupus Nephritis. New England Journal of Medicine. 1986; 314(10): 614–619.
  62. Miescher PA, Riethmueller D. Diagnosis and treatment of systemic lupus erythematosus. Semin Hematol. 1965; 2: 1–28.
  63. Cruchaud A, Pometta D, Rousso C, et al. Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions. Helv Med Acta. 1967; 34(1): Suppl:141–Suppl:142.
  64. Petschner F, Walker UA, Schmitt-Gräff A, et al. Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab. Dtsch Med Wochenschr. 2001; 126(37): 998–1001.
  65. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000; 343(16): 1156–1162.
  66. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011; 57(2): 235–244.
  67. Navarra SV, Guzmán RM, Gallacher AE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767): 721–731.
  68. String of successful trials in SLE: have we cracked the code? Lupus Science & Medicine [Internet]. https://lupus.bmj.com/content/7/1/e000380 (26.11.2020).